RPI Finance readies launch of $1.1 billion term loan B-6 for Monday

By Sara Rosenberg

New York, March 1 – RPI Finance Trust (Royalty Pharma) is set to hold a lender call at 10 a.m. ET on Monday to launch a $1.1 billion six-year term loan B-6, according to a market source.

Bank of America Merrill Lynch is the lead bank on the deal.

Proceeds will be used to help fund the acquisition of Perrigo Co. plc’s rights to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri for $2.2 billion in cash at closing and up to $650 million in potential milestone payments based upon future global net sales of Tysabri during 2018 and 2020.

Closing is expected in the next 30 days.

Royalty Pharma is a New York-based acquirer of royalty interests in marketed and late-stage biopharmaceutical products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.